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Abstract
Background: A highly efficient CRISPR/Cas9-based marker-free genome editing system has been established in
Plasmodium falciparum (Pf). However, with the current methods, two drug-selectable markers are needed for
episome retention, which may present hurdles for consecutive genome manipulations due to the limited number
of available selectable markers. The loading capacity of donor DNA is also unsatisfactory due to the large size of the
Cas9 nuclease and sgRNA co-expression system, which limits the size of knock-in DNA fragments. Because of the
inefficient end joining (EJ) DNA repair mechanism of Pf, a suicide-rescue approach could be used to address the
challenges. Cas9 nuclease and sgRNA were co-expressed from a single plasmid (suicide vector) with one selectable
marker, and the donor DNA was ligated into the other plasmid (rescue vector) containing only the ampicillin-
resistance gene (AmpR) and a ColEl replication origin (ori). Nonetheless, whether this approach can mediate even
the regular gene editing in Pf remains unknown. This study aimed to demonstrate the basic gene editing function
of this Cas9-mediated suicide-rescue system.
Findings: The suicide and rescue vectors were constructed and co-transfected into Pf3D7. This system worked as
expected when used to disrupt the Pfset2 gene and to insert a green fluorescent protein-renilla luciferase (gfp-ruc)
fusion gene cassette of 3334 base pairs (bp) into the Pf47 locus, demonstrating that the suicide vector actually induced
double-strand breaks (DSBs) and that the rescue vector functioned without maintenance via drug selection.
Conclusions: The adapted marker-free CRISPR/Cas9 system with only a single episome-selectable marker performs
well as the current systems for general gene editing which lays a solid foundation for further studies including
consecutive gene manipulations and large gene knock-ins.
Keywords: Marker-free, CRISPR/Cas9, Plasmodium falciparum
Findings
Background
Malaria is still a major public health burden in many
countries, and the most lethal malaria parasite is
Plasmodium falciparum (Pf ) [1, 2]. An understanding
of the gene function of Pf and the performance of
pathogen genetic manipulations is essential for anti-
malaria drug and malaria vaccine development. The
traditional approach to genome modification in Pf
relies on single- or double-crossover recombination
[3, 4] and is time-consuming and labor intensive.
Moreover, the knock-in of larger gene cassettes with-
out selectable marker integration is impractical using
such strategies.
The newly developed genome-editing technology
CRISPR/Cas9 has been successfully used in Pf and ex-
hibits higher efficiency. Transgenic parasites can be
obtained within a typical timeframe of 3–6 weeks,
and both marker-integrated and marker-free systems
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are available [5, 6]. In the system developed by Ghor-
bal et al. [5], Cas9 nuclease and sgRNA are expressed
under the endogenous Hsp86 and U6 promoters and
form a complex with targeted DNA strands to induce
double-strand breaks (DSBs) with high efficiency. This
process results is considerable target gene replace-
ment with the drug-selectable marker-cassette human
dihydrofolate reductase (hdhfr). Site-specific mutation
without the integration of a selectable marker can
also be efficiently achieved by maintaining the
CRISPR/Cas9 system and the donor DNA loading
plasmids as episomes using two selectable markers,
hdhfr and yeast dihydroorotate dehydrogenase
(yDHODH). In another CRISPR/Cas9 system for Pf
adapted by Wagner et al. [6], T7 RNA polymerase
(T7 RNAP) is introduced for sgRNA transcription.
As a marker-free genome-editing tool, blasticidin S
deaminase (bsd) and neomycin phosphotransferase
(neo) are employed to maintain the plasmids carrying
the T7 RNAP transcribe system, CRISPR/Cas9 system
and donor DNA. This T7 RNAP-dependent system
yields 50–100 % gene knockout frequencies within
the usual time frame. The successful application of
this powerful tool promises to accelerate both basic
and applied Pf research.
However, the current CRISPR/Cas9 systems may
not be competent for consecutive genome manipula-
tions in Pf due to the limited number of available se-
lection markers and potential drug incompatibility.
Moreover, the loading capacity for donor DNA is also
unsatisfactory; indeed, current systems may not accept
larger exogenous DNA fragments for knock-in. As de-
scribed above, in the system developed by Wagner et
al. [6], T7 RNAP is used for sgRNA transcription,
and two plasmids requiring two drugs that must be
simultaneously administered for episome retention
are used. Additionally, the loading capacity for the
donor DNA fragment is limited because the donor
plasmid must accept the expression cassettes of the
T7 RNAP gene and the drug-selectable marker. The
system constructed by Ghorbal et al. [5] is relatively
compact due to the use of the endogenous U6 pro-
moter to transcribe the sgRNA, but it also involves
two plasmids with two markers and allows limited
space for the donor DNA. Although marker-free edit-
ing can now be achieved, it may be difficult to per-
form multiple consecutive genome manipulations,
and larger gene cassette knock-ins might suffer tech-
nical hurdles.
It has been reported that none of the proteins re-
quired for the canonical non-homologous end joining
(C-NHEJ) pathway have been identified in Pf [7–9].
The efficiency of EJ DNA repair seems extremely low,
although an alternative EJ pathway has been found in
Pf [6, 9, 10]. In view of the inefficient EJ DNA repair
in Pf, a suicide-rescue approach might be appropriate
to address these challenges. A common feature of the
two systems is that Cas9 nuclease and sgRNA are not
co-expressed by a single plasmid perhaps because the
plasmid may be too large to be manipulated and may
impair the transfection efficiency. If Cas9 nuclease
and the sgRNA were encoded on the same plasmid
along with the drug selection marker, the site-specific
breaks could be induced by just one plasmid (a
suicide vector). When the suicide vector is co-
transfected with an independently established donor
plasmid (a rescue vector) containing the homology
arms without another selectable marker, the parasites
that receive both plasmids may survive and be se-
lected under drug pressure; the other parasites would
die due to the drug or inefficient end-joining DNA
repair. Because plasmids lacking the selectable marker
would be lost rapidly [8], recovering parasites would
theoretically suffer DNA breaks and homologous re-
combination would occur. The suicide vector would
be maintained as an episome, and the next round of
genome editing could proceed with the same system
but with another drug-selectable marker. Because the
donor plasmid is specialized, it can support larger se-
quences for knock-ins into Pf. The basic gene editing
function of this suicide-rescue approach has been
proved using ZFN-mediated gene replacement without
a selectable phenotype in Pf [11]. However, whether
the Cas9-mediated suicide-rescue system can perform
regular gene editing in Pf remains unknown. The
present study aims to confirm the regular ability of
the Cas9-mediated suicide-rescue system and to pro-
vide a selectable marker saving, easily operated and
low-cost marker-free genome editing tool for Pf that
may be more suitable for consecutive gene manipula-




pCas9-BSD-sgRNA (pCBS), the plasmid for Cas9 nu-
clease, bsd and sgRNA co-expression, was generated
in two steps. pL6BSD was first constructed by re-
placing the hdhfr cassette of pL6-eGFP [5] with the
bsd cassette from pCC4 [12] at the restriction sites
Sac II and Nco I. Then, the yfcu-coding sequence of
pL6BSD was replaced with the Cas9 nuclease open read-
ing frame (ORF) from pUF1-Cas9 [5] using the restriction
sites Xho I and Kpn I.
For both targets, pCBS-Pfset2 and pCBS-Pf47 were
made by replacing the BtgZ I-adaptor with guide
DNA sequence as previously described [5]. The oligo-
nucleotides used for Pfset2 and Pf47 were P9/P10
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(Additional file 1) and P11/P12, respectively. pGCBS-
Pfset2 was derived from pCBS-Pfset2 via the addition
of a Thosea asigna virus 2A peptide (GFP-2A)-coding
sequence that was amplified using P31/P32 from
pBSDv2.1–3 (Additional file 2) at the restriction site
Xho I upstream of the Cas9 ORF.
To produce the donor plasmid pARM-Pfsets, the
left and right homology arms were amplified using
P13/P14 and P15/P16, respectively, from the genomic
DNA of Plasmodium falciparum strain 3D7. The two
arms were ligated into an intact donor DNA via
overlap PCR using P13/P16, and they were then con-
nected to the ‘Ampicillin-resistance gene-ColE1 repli-
cation origin’ (‘AmpR-ColE1 ori’) fragment, which was
amplified using P17/P18 from the commercial T-
vector. To detect homologous recombination (HR), a
48-bp DNA fragment was introduced between the
arms using P14 and P15. The other donor plasmid,
pARM-GFP/RUCki, was constructed by ligating the
‘AmpR-ColE1 ori’ fragment with the gfp-ruc fusion
cassette flanked by the homology arms. The left arm,
right arm and Pf elongation factor 1-alpha (Pfef1α;
[PlasmoDB: PF13_0304]) 5’ untranslated region (UTR)
were amplified using P19/P20, P21/P22, and P23/P24
from the genomic DNA of 3D7. The gfp ORF, renilla
luciferase ORF and Plasmodium berghei dihydrofolate
reductase (Pbdhfr; [PlasmoDB: PBANKA_0719300])
terminator (PbDT) were amplified from pLN-GFP
(Additional file 2), pHBRIH and the genomic DNA of
P. berghei ANKA using P25/P26, P27/P28, and P29/
P30, respectively. All cloning reactions used the Clo-
nExpress II One-Step Cloning Kit (Vazyme) and
XL10-competent cells (Vazyme).
Parasite culture and transfections
Pf strain 3D7 parasites were routinely cultured in fresh
human red blood cells under 5 % O2 and 5 % CO2 in
RPMI-1640 media supplemented with 5 g/L Albumax
I (Thermo Fisher Scientific), 2 g/L NaHCO3, 25 mM
HEPES, 1 mM hypoxanthine and 50 mg/L gentami-
cin. The transfections used ~100 μg of each plasmid
and were performed by the spontaneous DNA uptake
method [13]. The transfectants were obtained by se-
lection with 5.0 μg/mL blasticidin S (Thermo Fisher
Scientific).
Whole-cell PCR analysis
Mutant parasites were verified by PCR using PrimeS-
TAR GXL DNA Polymerase (Takara Bio, Inc.) accord-
ing to the manufacturer’s instructions. The parasites
used as PCR templates were prepared as previously
described [14], and cultures at 0.1–10 % parasitaemia
and 2 % hematocrit were centrifuged at 350 × g for
3 min. The pellets were flash-frozen in liquid nitro-
gen and then thawed, and 1 μL of the lysed cells was
quickly added to 50 μL of the PCR reaction solution
on ice to yield a final concentration of 1× PrimeSTAR
GXL Buffer. The primers used to detect the Pfset2
disruption were P1/P2, P3/P4 and P1/P4. The primers
used to detect the gfp-ruc fusion cassette knock-in
were P5/P6, P7/P8 and P5/P8. The PCR products
yielded by P1/P4 and P5/P8 were purified using an
agarose gel extraction kit and sequenced using the
same primers.
Fluorescence-activated cell sorting (FACS) of GFP-positive
parasites
The parasite cultures were centrifuged at 350 × g for
3 min, washed, and resuspended with phosphate-
buffered saline to a concentration of 1.0 × 106 cells/mL.
The GFP-positive parasites were sorted with a FAC-
SAria™ II flow cytometer and then used for whole-cell
PCR analysis as described above.
Live cell fluorescence microscopy/laser confocal microscopy
The parasite cultures were incubated for 10 min with
RPMI medium containing 2 μg/mL Hoechst 33,342
(Sigma) at 37 °C and then washed twice with PBS and
applied to a 3.5-cm culture dish (Nunc). Imaging was
conducted immediately at room temperature using a
Nikon Ti-S inverted microscope or a Zeiss 710 NLO
laser confocal microscope.
Luciferase assay
Renilla luciferase expression was confirmed using the
Renilla Luciferase Assay System (Promega). The para-
site samples were prepared by centrifugation of the
cultures at ~5 % parasitaemia and 2 % hematocrit.
Next, 15-μL pellets were either used immediately or
stored at −80°C.
Results and discussion
We first redesigned and successfully constructed the
basic suicide vector pCas9-BSD-sgRNA (pCBS) con-
sisting of the expression cassettes for the sgRNA, Cas9
nuclease and blasticidin S deaminase. These genes
were driven by endogenous promoters. To test the
function of this suicide-rescue system, Pfset2 was
chosen as a target because it has been demonstrated to
be a nonessential gene for in vitro blood-stage survival
of Pf [15]. The suicide vector pGFP-CBS-Pfset2 with a
gfp reporter gene was derived from pCBS-Pfset2. The
donor DNA template consisting of homology arms
flanking the Avi-tag was provided by a rescue plasmid,
pARM-SET2ko, without a drug-selectable marker for
Pf (Fig. 1a). pGFP-CBS-Pfset2 and pARM-SET2ko
were co-transfected, and blasticidin S selection was
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applied. The drug-resistant parasites were collected
approximately 4 weeks after transfection, and PCR re-
sults confirmed integration of the Avi-tag. However,
the truncated locus was nearly undetectable (Fig. 1b).
The proportion of edited parasites exhibited an
increasing upward tendency as indicated by the subse-
quent PCR detection (Fig. 1b). One week later, the
truncated locus became highly visible (Fig. 1b), and
GFP-positive parasites were observed by confocal mi-
croscopy (Fig. 1c). The GFP-positive parasites obtained
Fig. 1 Redesigned marker-free CRISPR/Cas9-mediated deletion of the Pfset2 locus. a Construct used for Pfset2 gene disruption. Introns 1 to 4
of the Pfset2 locus are represented as gray boxes. pGFP-CBS-Pfset2 was designed to induce a double-strand break (DSB) near the 5’ end of
intron 2. The Avi-tag between the homology arms was added to detect donor integration in the design of the PCR primers. Pf U6 5’, Pf U6
spliceosomal RNA promoter region; Pf CAM5’, Pf calmodulin promoter region; Pf Hsp86 5’, Pf heat shock protein 86 promoter region; AmpR,
ampicillin resistance gene; ori, replication origin; ko, knockout. The positions and directions of the primers P1 to P4 are indicated by the small
black arrows. b PCR analysis of the parasite populations obtained after transfection. WT, wild-type; SET2Δ, Pfset2 knockout; d31, d38, d47, and
d61, days 31, 38, 47, and 61 after transfection, respectively; FACS: fluorescence-activated cell sorting. c Laser confocal microscopy of the
parasites expressing the GFP protein. d DNA sequencing confirmed a 1.5-kb deletion in the Pfset2 gene. The top panel shows the partial
nucleotide sequences of the left and right arms from the parental strain. The bottom panel shows the 48-bp DNA insert between the left and
right arms
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by FACS were determined to be edited; no wild-type
(WT) loci were detected (Fig. 1b). Additionally, se-
quencing results indicated the expected editing events
(Fig. 1d). The PCR results at day 47 revealed that the
mutant parasites became dominant, and the WT locus
was nearly undetectable after day 61 (Fig. 1b). To-
gether, these results indicate that the suicide vector
actually induced DSBs and that the rescue plasmid
also performed well, although it was transiently sup-
plied. Thus, a marker-free genome editing system
with only one selectable marker was successfully cre-
ated. This experiment demonstrated once again that
the EJ mechanism of Pf is very inefficient.
Currently, the following five drug-selectable markers
are available for Pf: hdhfr [16], bsd [17], neo [17],
yDHODH [18], and puromycin-N-acetyltransferase
(PAC) [19]. Theoretically, at least five rounds of con-
secutive manipulations could be supported by the
suicide-rescue system with each requiring one drug
for selection and without consideration for the drug
compatibility. Previous systems [5, 6] might support
up to 4 rounds of editing, but the Cas9 nuclease-
expressing episome had to be stably maintained be-
yond the first round of transfection, which might lead
to exogenous plasmid integration into the parasite
genome.
The suicide-rescue editing system has also been
used to mediate the insertion of a gfp-ruc fusion gene
cassette (a 3337-bp DNA fragment) into the Pf47
locus of Pf [20] (Fig. 2a). Live parasites were obtained
approximately 4 weeks after transfection. Luciferase
assay and fluorescence microscopy results indicated
that both genes were functionally expressed (Fig. 2c,
d). PCR and sequencing confirmed the insertion of
the fusion gene cassette. The WT locus was still de-
tectable at day 51 but was undetectable approximately
12 days later (Fig. 2b). A parallel transfection experi-
ment yielded similar results, and the WT locus was
also undetectable by PCR at day 60. These results
illustrate that the redesigned system was capable of
mediating the knock-in of larger exogenous gene
cassettes and that the extended size of the donor
plasmid did not obviously impair the efficiency of co-
transfection. Exogenous gene knock-in and endogen-
ous add-back are typically performed in studies of Pf,
but the donor DNA loading capacities of previous
systems might limit the sizes of inserted fragments to
10 kilobases (kb) for the donor DNA loading plasmids
have exceeded 9.0 kb [5] or even 11.0 kb [6]. The
rescue plasmid used in this study contains only a 2.1-
kb ‘AmpR-ori’ backbone and thus is capable of pro-
viding 7.0 kb or 9 kb of extra capacity.
The editing efficiency was not directly assayed in
this study. Obviously, the proportion of the parasite
population that exhibited editing was dependent on
the drug selection time as was observed in both the
knock-out and knock-in experiments. According to
the previous report, high gene-disruption frequencies
(≥ 50–100 %) can be achieved within the usual time-
frame (4–6 weeks) using marker-free CRISPR/Cas9
editing [6]. In our study, the edited population be-
came dominant (≥ 50 %) in approximately 6–7
weeks, as demonstrated by PCR analysis, and this
timeframe is similar to the typical timeframe. Thus it
can be seen that the regular drug selection time is
not always sufficient for obtaining highly pure edited
population (~100 % editing efficiency) in both previ-
ous and redesigned system. In order to avoid the
possible plasmid integration, limit dilution and cul-
ture without drug pressure should be employed when
the gene modified parasites are detectable within the
usual timeframe. This process usual needs nearly a
month of time for obtaining single-clone parasites
with considerable amount for genetic analysis [21]
and for next round gene editing. However, this strat-
egy is time consuming and labor intensive because
multi-round limited dilution would be needed in
consecutive gene manipulation. An alternative
method is a compact gene editing process without
interruption with limited dilution following the last
round manipulation, but the prerequisite is that the
highly pure edited population has been generated in
the previous gene manipulation. Thus in our study
the drug selection time was extended to confirm
whether the highly pure edited population could be
obtained and how long it would take. In both experi-
ments the time required for the total elimination of
the WT parasites (i.e. below the level detectable by
PCR) was approximately 9 weeks. This strategy
shows no advantages in time consumption compared
with limited dilution dependent approach, unless the
selection time could be reduced to the usual time-
frame. It can be speculated that this extended elimin-
ation time was attributable to spontaneous drug
resistance in the WT parasite. The GFP-positive par-
asites obtained by FACS in the knock-out test were
part of a highly pure mutant population, which indi-
cated that the 2.9-kb untruncated locus was ampli-
fied from spontaneously occurring blasticidin-
resistant parasites. It has been reported that blastici-
din pressure results in resistant transport mutant se-
lection in the FCB strain of Pf [22], and 3D7 may
also acquire blasticidin resistance through mutation.
The time required to reach 100 % edited parasites
might be reduced by appropriately increasing the
blasticidin concentration.
In conclusion, a suicide-rescue-based marker-free
CRISPR/Cas9 system was developed and confirmed
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to be competent for general gene manipulations in
Pf. This system requires fewer selectable markers
and exhibits potential for large gene cassette knock-
ins. This tool may be a useful alternative to Pf gen-
ome editing. However, further experiments are
needed to confirm whether this system could effi-
ciently mediate consecutive gene manipulations and
large gene cassette knock-ins. Although a CRISPR/
Cas9 system has been established in Pf, we call for
additional studies to increase the efficiency and ver-
satility of this system.
Additional files
Additional file 1: PCR primers used in this study. (PDF 35 kb)
Additional file 2: sequences of pBSDv2.1-3 and pLN-GFP. (PDF 60 kb)
Abbreviations
2A: Thosea asigna virus 2A peptide; bsd: blasticidin S deaminase;
C-NHEJ: canonical non-homologous end joining; DSBs: double-strand breaks;
EJ: end joining; FACS: fluorescence-activated cell sorting; gfp-ruc: green
fluorescent protein-renilla luciferase; hdhfr: human dihydrofolate reductase;
HR: homologous recombination; neo: neomycin phosphotransferase;
PAC: puromycin-N-acetyltransferase; Pb: Plasmodium berghei; Pf: Plasmodium
falciparum; T7 RNAP: T7 RNA polymerase; yDHODH: yeast dihydroorotate
dehydrogenase; yfcu: yeast cytosine deaminase and uridyl phosphoribosyl
transferase.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JL participated in the experimental design and performed the experiments
with contributions from YT, JP and YY. QL, XT and SZ helped with the
experimental setup and provided reagents. XC and LiQ supervised all aspects
of this study, including the study design, execution, data interpretation and
manuscript preparation. All authors have read and approved the final
manuscript.
Acknowledgments
This work was supported by the National Natural Science Foundation of
China (No. 31570925, No. 81372451) and the Guangzhou Municipal Funds of
Science and Technology (No. 201300000098). We thank Jose-Juan Lopez-
Rubio and Mehdi Ghorbal for kindly providing the pUF1-Cas9 and pL6-eGFP
plasmids. We thank Xu Zhang at Jilin University for providing plasmid pHBRIH
and for technical assistance. We extend special thanks to Lubin Jiang and his
group at the Institute Pasteur of Shanghai for help with the P. falciparum
transfection experiments. We are also grateful to Yi Zheng and Hongwen Pang
at the Instrument Center of GIBH for assistance with the use of the instruments.
Author details
1Laboratory of Pathogen Biology, State Key Laboratory of Respiratory Disease,
Center for Infection and Immunity, Guangzhou Institutes of Biomedicine and
Health (GIBH), Chinese Academy of Sciences, No. 190 Kaiyuan Avenue,
Guangzhou Science Park, Guangzhou 510530, Guangdong Province, China.
2CAS Lamvac Biotech Co., Ltd, No. 3 Lanyue Road, Guangzhou Science Park,
Guangzhou 510530, Guangdong Province, China.
Received: 16 February 2016 Accepted: 1 April 2016
References
1. Sharma D, Lather M, Mallick PK, Adak T, Dang AS, Valecha N, et al.
Polymorphism in drug resistance genes dihydrofolate reductase and
dihydropteroate synthase in Plasmodium falciparum in some states of India.
Parasites Vector. 2015;8:471.
2. Mancini MV, Spaccapelo R, Damiani C, Accoti A, Tallarita M, Petraglia E, et al.
Paratransgenesis to control malaria vectors: a semi-field pilot study. Parasites
Vector. 2016;9(1):140.
3. Wu YM, Kirkman LA, Wellems TE. Transformation of Plasmodium falciparum
malaria parasites by homologous integration of plasmids that confer
resistance to pyrimethamine. Proc Natl Acad Sci USA. 1996;93(3):1130–4.
4. Duraisingh MT, Triglia T, Cowman AF. Negative selection of Plasmodium
falciparum reveals targeted gene deletion by double crossover
recombination. Int J Parasitol. 2002;32(1):81–9.
5. Ghorbal M, Gorman M, Macpherson CR, Martins RM, Scherf A, Lopez-Rubio
JJ. Genome editing in the human malaria parasite Plasmodium falciparum
using the CRISPR-Cas9 system. Nat Biotechnol. 2014;32(8):819–21.
6. Wagner JC, Platt RJ, Goldfless SJ, Zhang F, Niles JC. Efficient CRISPR-Cas9-
mediated genome editing in Plasmodium falciparum. Nat Methods. 2014;
11(9):915–8.
7. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. Genome
sequence of the human malaria parasite Plasmodium falciparum. Nature.
2002;419(6906):498–511.
8. Aravind L, Iyer LM, Wellems TE, Miller LH. Plasmodium biology: genomic
gleanings. Cell. 2003;115(7):771–85.
9. Kirkman LA, Lawrence EA, Deitsch KW. Malaria parasites utilize both
homologous recombination and alternative end joining pathways to
maintain genome integrity. Nucleic Acids Res. 2014;42(1):370–9.
10. Zhang C, Xiao B, Jiang YY, Zhao YH, Li ZK, Gao H, et al. Efficient editing of
malaria parasite genome using the CRISPR/Cas9 system. Mbio. 2014;5(4):
e01414–14.
11. Straimer J, Lee MCS, Lee AH, Zeitler B, Williams AE, Pearl JR, et al.
Site-specific genome editing in Plasmodium falciparum using engineered
zinc-finger nucleases. Nat Methods. 2012;9(10):993.
12. Maier AG, Braks JAM, Waters AP, Cowman AF. Negative selection using
yeast cytosine deaminase/uracil phosphoribosyl transferase in Plasmodium
falciparum for targeted gene deletion by double crossover recombination.
Mol Biochem Parasit. 2006;150(1):118–21.
13. Deitsch KW, Driskill CL, Wellems TE. Transformation of malaria parasites by
the spontaneous uptake and expression of DNA from human erythrocytes.
Nucleic Acids Res. 2001;29(3):850–3.
14. Caro F, Miller MG, DeRisi JL. Plate-based transfection and culturing technique
for genetic manipulation of Plasmodium falciparum. Malar J. 2012;11:22.
15. Jiang LB, Mu JB, Zhang QF, Ni T, Srinivasan P, Rayavara K, et al. PfSETvs
methylation of histone H3K36 represses virulence genes in Plasmodium
falciparum. Nature. 2013;499(7457):223.
(See figure on previous page.)
Fig. 2 Redesigned marker-free CRISPR/Cas9-mediated insertion of the gfp-ruc fusion gene cassette at the Pf47 locus. a Construct used for
gfp-ruc fusion gene cassette insertion into the Pf47 locus. pCBS-Pf47 was designed to target the Pf47 ORF at its 5’ terminal-region,
~150 bp from the start codon. pARM-GFP/RUCki provides a donor fragment with the gfp-ruc fusion cassette flanked by homology arms.
The positions and directions of primers P5 to P8 are indicated by small black arrows. Pf EF1α 5’, Pf elongation factor 1-alpha promoter
region; PbDT 3’, Pb dihydrofolate reductase terminator; ki, knock-in. (b) PCR analysis of the parasite populations obtained after transfection.
d51 and d63, days 51 and 63 after transfection, respectively. (c) Luciferase assay confirming the functional expression of the integrated
ruc gene in the parasites obtained after transfection. The negative control was 3D7 WT. The luciferase assays were performed in triplicate,
and the standard deviations are indicated by vertical bars. (d) Live cell fluorescence microscopy of the parasites expressing the GFP
protein. The negative control was 3D7 WT
Lu et al. Parasites & Vectors  (2016) 9:198 Page 7 of 8
16. Fidock DA, Wellems TE. Transformation with human dihydrofolate reductase
renders malaria parasites insensitive to WR99210 but does not affect the
intrinsic activity of proguanil. Proc Natl Acad Sci USA. 1997;94(20):10931–6.
17. Ben Mamoun C, Gluzman IY, Goyard S, Beverley SM, Goldberg DE. A set of
independent selectable markers for transfection of the human malaria parasite
Plasmodium falciparum. Proc Natl Acad Sci USA. 1999;96(19):10944–4.
18. Ganesan SM, Morrisey JM, Ke HJ, Painter HJ, Laroiya K, Phillips MA, et al.
Yeast dihydroorotate dehydrogenase as a new selectable marker for
Plasmodium falciparum transfection. Mol Biochem Parasit. 2011;177(1):29–34.
19. de Koning-Ward TF, Waters AP, Crabb BS. Puromycin-N-acetyltransferase as
a selectable marker for use in Plasmodium falciparum. Mol Biochem Parasit.
2001;117(2):155–60.
20. Talman AM, Blagborough AM, Sinden RE. A Plasmodium falciparum strain
expressing GFP throughout the Parasite's life-cycle. PloS One. 2010;5(2):
e9156.
21. Doolan DL. Malaria methods and protocols. Totowa, N.J.: Humana Press;
2002.
22. Hill DA, Pillai AD, Nawaz F, Hayton K, Doan L, Lisk G, et al. A blasticidin
S-resistant Plasmodium falciparum mutant with a defective plasmodial
surface anion channel. Proc Natl Acad Sci USA. 2007;104(3):1063–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lu et al. Parasites & Vectors  (2016) 9:198 Page 8 of 8
